Background
==========

Activin A, a pleiotrophic cytokine belonging to the transforming growth factor-beta (TGF-β) superfamily, is synthesized by many cell types throughout the body \[[@B1],[@B2]\]. The molecular structure is a disulphide-linked, homodimeric glycoprotein composed of two inhibin βA chains. Activin A was first recognized as an endocrine factor, but is now known to be essential to developmental and repair processes, and total ablation is neonatal lethal \[[@B3]\]. Contrasting regulatory roles have been cited for Activin A in inflammation \[[@B4]\]. Human monocytes synthesize activin A upon stimulation with classical M1 macrophage activation inducers such as GM-CSF, LPS, and IFNγ \[[@B5],[@B6]\]. Exposure of GM-CSF treated macrophages to anti-Activin A reduces M1 markers and enhances alternative M2 phenotype markers such as IL-10 \[[@B7]\]. Activin A also inhibits monocyte production of IL-1β and enhances IL-1 receptor antagonist production \[[@B8]\]. Interestingly, in severe asthma, activin A may be elevated in serum, and data from animal models suggests that activin A may suppress T helper 2 (Th2) mediated allergic responses \[[@B9]\]. Collectively these observations suggest multifunctional roles for activin A in inflammatory processes.

Maintenance of lung homeostasis is a complex process dependent upon a network of interacting cells and cytokines. GM-CSF is required for alveolar macrophage (AM) function and pulmonary homeostasis \[[@B10]\]. In genetically altered mice homozygous for a disrupted GM-CSF gene (GM-CSF knockout), hematopoiesis is normal but there is accumulation of excess lung surfactant \[[@B11],[@B12]\]. This surfactant pathology mirrors that of human PAP, an autoimmune disease characterized by high levels of autoantibody to GM-CSF \[[@B12]-[@B14]\]. Aerosolized GM-CSF resolves the pulmonary pathology of GM-CSF knockout mice, thus demonstrating that surfactant homeostasis can be influenced by local administration of GM-CSF to the respiratory tract \[[@B15]\].

Previously we reported that healthy human AMs synthesize activin A in response to GM-CSF but AMs of patients with PAP are deficient in activin A \[[@B16]\]. In addition, PAP AMs are deficient in the nuclear transcription factor, Peroxisome Proliferator-activated Receptor, (PPARγ), a regulator of lipid and glucose metabolism that is restored by GM-CSF treatment \[[@B17]\]. PPARγ has also been shown to be a negative regulator of inflammation \[[@B18],[@B19]\]. Interestingly, alveolar macrophages of GM-CSF knockout mice are also deficient in PPARγ \[[@B20]\]. The role of activin A in the lung has not been established. Because of the phenotypic similarities between human PAP and the GM-CSF knockout mouse, this study was undertaken to investigate activin A regulation in the lung. Initially, it was hypothesized that activin A might be impaired in GM-CSF knockout mice based upon previous data from PAP studies \[[@B16]\].

Results
=======

Activin A and IFNγ are intrinsically elevated in GM-CSF knockout mice as compared to wild-type mice
---------------------------------------------------------------------------------------------------

Unlike previous findings of activin A deficiency in human PAP \[[@B16]\], activin A mRNA expression of BAL cells was significantly (p \<0.005) elevated in GM-CSF knockout mice compared to wild-type controls (Figure [1](#F1){ref-type="fig"}A). Quantification of activin A protein in BAL fluids confirmed mRNA findings with significantly (p \< 0.05) elevated protein levels in GM-CSF knockout compared to wild-type (Figure [1](#F1){ref-type="fig"}B). GM-CSF knockout expression of follistatin, an inhibitor of activin A \[[@B21]\], was similar to wild-type mice (data not shown) and thus could not account for the striking elevation of activin A.

![**Activin A and IFNγ are intrinsically elevated in GM-CSF knockout lung compared to wild-type mice.** Expression of mRNA is shown as a relative fold change as calculated from qPCR. **(A)** Activin A mRNA expression of BAL cells. **(B)** Levels of activin A protein in BAL fluids were quantified by ELISA. **(C)** IFNγ mRNA expression of BAL cells. **(D)** Cytospin preparations of wild-type C57Bl/6 and GM-CSF knockout BAL cells were stained with anti-IFNγ (green) and DAPI (blue), a nuclear counterstain. Elevated IFNγ protein can be seen in GM-CSF knockout BAL cells (right) compared to wild-type (left).](1471-2172-14-41-1){#F1}

Intrinsic factors that could potentially affect activin A levels were subsequently investigated in GM-CSF knockout mice. Macrophage colony-stimulating factor (M-CSF) has been reported to be upregulated in GM-CSF knockout mice \[[@B22]\]. Examination of M-CSF in the current study, however, indicated no effect on activin A *in vitro* in either wild-type or GM-CSF knockout AMs (data not shown). Elevated IFNγ has been reported in lungs of GM-CSF knockout mice \[[@B23]\] therefore intrinsic levels of IFNγ were examined. IFNγ mRNA expression was significantly (p \< 0.005) elevated in GM-CSF knockout BAL cells compared to wild-type controls (Figure [1](#F1){ref-type="fig"}C). Immunocytochemistry of GM-CSF knockout BAL cells confirmed mRNA results and indicated markedly increased expression of intracellular IFNγ protein compared to wild-type (Figure [1](#F1){ref-type="fig"}D).

IFNγ is not elevated in human PAP BAL cells
-------------------------------------------

In contrast to results from GM-CSF knockout mice, examination of IFNγ expression in human BAL cells from PAP patients revealed no significant increase compared to healthy controls (Figure [2](#F2){ref-type="fig"}).

![**Expression of IFNγ is not detectable in BAL cells from human PAP patients.** Expression of IFNγ mRNA in PAP patients (n = 6) did not significantly differ from that of healthy controls (n = 5).](1471-2172-14-41-2){#F2}

Activin A levels are enhanced by IFNγ and reduced by IFNγ blockade
------------------------------------------------------------------

IFNγ has been shown to upregulate activin A expression in human monocytes \[[@B5]\] but AMs have not been studied. Results from 24-hour *in vitro* cultures of wild-type AMs indicated that IFNγ (100 U/ml) significantly (p \< 0.05) increased activin A expression (Figure [3](#F3){ref-type="fig"}A). To determine whether blockade of IFNγ with specific anti-IFNγ antibody would alter intrinsic activin A expression, unstimulated GM-CSF knockout AMs were cultured *in vitro* for 24 hours with irrelevant immunoglobulin (Ig) or anti-IFNγ. ELISA analysis of conditioned media indicated that anti-IFNγ reduced activin A protein synthesis compared to irrelevant Ig (Figure [3](#F3){ref-type="fig"}B) confirming that IFNγ blockade reduced intrinsic activin A production.

![**Activin A levels are increased by IFNγ and reduced by IFNγ blockade. (A)** IFNγ upregulates activin A mRNA in wild-type alveolar macrophages cultured for 24 hours with IFNγ (100 U/ml) \[n = 4\]. **(B)** Antibody to IFNγ represses intrinsic activin A synthesis in GM-CSF knockout alveolar macrophages. GM-CSF knockout alveolar macrophages were cultured with irrelevant IgG or anti-IFNγ for 24 hours and activin A was determined in conditioned media by ELISA (n = 2). **(C)** BAL cells from GM-CSF knockout mice receiving intratracheal instillation of lentivirus-PPARγ or control lentivirus-EGFP were analyzed for IFNγ and activin A mRNA expression at 10 days post-transduction (n = 5).](1471-2172-14-41-3){#F3}

Because activin A is intrinsically elevated in PPARγ deficient GM-CSF knockout mice but severely decreased in PPARγ deficient human PAP patients \[[@B16]\], it appeared unlikely that PPARγ would exert a direct effect on activin A. Observations made elsewhere \[[@B24]\] also found no evidence of a PPARγ effect on activin A. We have shown, however, that IFNγ is elevated in macrophage-specific PPARγ knockout mice and significantly reduced after *in vivo* restoration of PPARγ via a lentivirus vector \[[@B25]\]. We utilized this approach to determine whether PPARγ restoration in GM-CSF knockout mice might reduce IFNγ and thereby reduce activin A. Results supported this action. Ten days post intratracheal inoculation of lentivirus reagents into GM-CSF knockout mice, BAL cell mRNA expression of both IFNγ and activin A was significantly reduced in animals receiving lentivirus-PPARγ compared to controls receiving lentivirus-eGFP (p \< 0.05) (Figure [3](#F3){ref-type="fig"}C).

Human alveolar macrophage activin A is increased by IFNγ
--------------------------------------------------------

While the above studies clearly defined IFNγ-mediated regulation of activin A in murine alveolar macrophages, it was necessary to confirm this pathway in human alveolar macrophages. *In vitro* studies demonstrated that IFNγ significantly enhanced activin A protein production (Figure [4](#F4){ref-type="fig"}) in healthy human alveolar macrophages. Thus activin A synthesis in both human and murine alveolar macrophages is responsive to IFNγ upregulation even though intrinsic activin A levels differ between human and mouse.

![**Human alveolar macrophages from healthy donors produce activin A in response to IFNγ.** Activin A protein is increased in conditioned media from human alveolar macrophages cultured with IFNγ (1000 U/ml) for 24 hours *in vitro*.](1471-2172-14-41-4){#F4}

GM-CSF BAL cells show intrinsic elevation of both M1 and M2 macrophage phenotypic markers
-----------------------------------------------------------------------------------------

We and others reported previously that M-CSF gene expression and protein, a cytokine associated with the M2 macrophage phenotype, was elevated in GM-CSF knockout mice \[[@B22],[@B26]\]. Current data indicate that the M1-associated cytokine, IFNγ (protein and gene expression) is also increased in these mice. Therefore, it was unclear whether GM-CSF knockout BAL cells would express predominantly M1 or M2 profiles. To address this issue, we determined mRNA expression of several M1 and M2 markers in GM-CSF knockout BAL cells. With respect to M1 markers, we examined the IFNγ-regulated target gene, iNOS (Figure [5](#F5){ref-type="fig"}A), together with CCL5 (Figure [5](#F5){ref-type="fig"}B), and IL-6 (Figure [5](#F5){ref-type="fig"}C), and found that all were significantly elevated compared to wild-type mice. The M2 marker, IL-10, has been reported to be suppressed by elevated activin A \[[@B7],[@B27]\], and in PAP, activin A deficiency is accompanied by elevated IL-10 \[[@B16],[@B28],[@B29]\]. Surprisingly, analysis of IL-10 expression in GM-CSF knockout BAL cells revealed significantly elevated levels compared to wild-type mice (Figure [5](#F5){ref-type="fig"}D). Analysis of another M2-associated marker, CCL2, also indicated significant elevation compared to wild-type mice (Figure [5](#F5){ref-type="fig"}E). These results suggested that GM-CSF knockout alveolar macrophages might constitute a mixed population of both M1 and M2 phenotypes.

![**mRNA expression of both M1 and M2 macrophage phenotypic markers is intrinsically elevated in GM-CSF knockout BAL cells compared to wild-type mice.** Elevated mRNA expression of M1 markers: **(A)** iNOS; **(B)** CCL5, and **(C)** IL-6. Elevated mRNA expression of M2 markers: **(D)** IL-10, and **(E)** CCL2.](1471-2172-14-41-5){#F5}

Discussion
==========

The current findings suggest that IFNγ is a major contributory factor to the intrinsic elevation of activin A in AMs. Findings also point out a striking difference in activin A expression in human PAP and GM-CSF knockout mice despite common deficiencies of GM-CSF and PPARγ (summarized in Table [1](#T1){ref-type="table"}). In parallel with activin A, GM-CSF knockout mice displayed over-expression of IFNγ \[[@B23]\], a positive regulator of activin A \[[@B5]\]. In contrast, BAL cells of PAP patients do not exhibit elevated IFNγ and activin A is deficient \[[@B16]\].

###### 

Summary: comparison of macrophage activation regulatory factors in human pulmonary alveolar proteinosis (PAP) patients and GM-CSF knockout mice

   **Regulatory factors**   **Associated macrophage phenotype**                             **PAP patients**                             **GM-CSF knockout mice**
  ------------------------ ------------------------------------- ---------------------------------------------------------------------- --------------------------
         **GM-CSF**                       **M1**                                 Deficient protein, not mRNA \[[@B28]\]                     Absent \[[@B11]\]
       **Activin A**                      **M1**                                          Deficient \[[@B16]\]                                   Elevated
          **IL-6**                        **M1**                                                Not done                                         Elevated
          **CCL5**                        **M1**                                                Not done                                         Elevated
          **IFNγ**                        **M1**                          mRNA - not elevated (comparable to healthy controls)             Elevated \[[@B23]\]
          **INOS**                        **M1**                  Undetectable in human alveolar macrophages (unpublished observation)           Elevated
         **M-CSF**                        **M2**                                          Elevated \[[@B30]\]                              Elevated \[[@B22]\]
         **PPARγ**                        **M2**                                          Deficient \[[@B31]\]                             Deficient \[[@B31]\]
          **CCL2**                        **M2**                                          Elevated \[[@B32]\]                                    Elevated
         **IL-10**                        **M2**                                          Elevated \[[@B29]\]                                    Elevated
          **MMP2**                        **M2**                                          Elevated \[[@B33]\]                              Elevated \[[@B33]\]

Elevated IFNγ has been reported previously in the BAL fluids of GM-CSF knockout mice \[[@B23]\]. Our previous studies also found elevated IFNγ expression in macrophage-specific PPARγ knockout mice \[[@B25]\]. Restoration of PPARγ via lentivirus vector in these mice greatly diminished IFNγ expression \[[@B25]\]. In the current study, similar results were seen after PPARγ--lentivirus treatment of GM-CSF knockout mice. Such findings suggest that the PPARγ deficiency present in GM-CSF knockout mice may contribute to elevated IFNγ. GM-CSF has been shown to be a critical upregulator of PPARγ \[[@B31],[@B34]\]. The total lack of GM-CSF in knockout mice may maintain an extreme PPARγ deficiency which is ineffective at repressing inflammatory mediators such as IFNγ. In human PAP, IFNγ levels are not increased despite PPARγ deficiency, furthermore, GM-CSF is not totally absent \[[@B29]\]. The primary etiology of PAP is considered to be an autoimmune response to GM-CSF in the form of high levels of circulating, neutralizing autoantibody to GM-CSF \[[@B13]\]. It is also possible that additional regulatory mechanisms are present in human lung to help prevent IFNγ buildup in PAP.

The varying characteristics of activated macrophages have led to attempts to categorize activation phenotypes \[[@B35]-[@B39]\]. The M1 phenotype is characterized by production of microbial or IFNγ-triggered molecules such as iNOS and IL-12. GM-CSF has been cited as an inducer of M1 phenotypes while M-CSF has been shown to induce the M2 alternative activation phenotype in which IL-10 or TGFβ may be produced \[[@B7],[@B40]\]. We have shown that M-CSF is elevated in GM-CSF knockout mice \[[@B22]\] and in human PAP \[[@B33]\] which might suggest the presence of an M2 macrophage phenotype (see Table [1](#T1){ref-type="table"}). Interestingly, PPARγ, which is deficient in GM-CSF knockout mice, is also a major driver of the M2 phenotype \[[@B41]\]. It has been pointed out however, that macrophage phenotypes were defined by carefully controlled *in vitro* conditions which may be vastly different from the *in vivo* milieu \[[@B42]\]. Thus the juxtaposition of both IFNγ and M-CSF in the lungs of GM-CSF knockout mice could produce the novel combination of macrophage activation phenotypes illustrated by elevated M1 (iNOS, CCL5, IL-6) and M2 (IL-10, CCL2) markers (Table [1](#T1){ref-type="table"}). Other IFNγ-inducible pro-inflammatory mediators (chemokines CXCL9, CXCL10, and CXCL11) have been noted in the lungs of GM-CSF knockout mice \[[@B23]\]. Previously, we found that MMP-2, a matrix metalloproteinase associated with M-CSF and alternative M2 activation, is also elevated in GM-CSF knockout BAL cells \[[@B33]\].

Conclusions
===========

The current findings extend our previous studies examining pulmonary mechanisms operative in human PAP and the GM-CSF knockout mouse. It is clear that pathways of activin A regulation may utilize GM-CSF or IFNγ as stimulatory factors. In the GM-CSF knockout mouse, lack of GM-CSF may restrict production of sufficient PPARγ to control inflammation. The persistent elevation of both M-CSF and IFNγ may influence AMs to express characteristics of both M1 and M2 phenotypes. The current data emphasize the plasticity of alveolar macrophages in assuming a unique activation phenotype when regulatory pathways become dysfunctional.

Methods
=======

Mice
----

Animal studies were conducted in conformity with Public Health Service (PHS) Policy on humane care and use of laboratory animals and were approved by the institutional animal care committee. The GM-CSF knockout mice were generated by Dr. Glenn Dranoff and have been previously described \[[@B11]\]. Controls consisted of C57BL/6 wild type mice obtained from Jackson Laboratory (Bar Harbor, ME). BAL cells and fluids were obtained from 8-12 week-old GM-CSF knockout mice and age and gender matched wild-type C57BL/6 controls as previously described \[[@B43]\]. Briefly, cytospins of BAL cells were stained with a modified Wright-Giemsa stain for differentials. A minimum of 100 cells was scored for each lavage. Mean (± SEM) BAL cells from C57BL/6 mice were composed of 98 ± 1% macrophages and 2 ± 1% lymphocytes; GM-CSF knockout BAL cells were composed of 91 ± 2% macrophages and 5 ± 1% lymphocytes. For *in vitro* studies, BAL cells were plated at 150,000 cells/well in 48-well plates as previously described \[[@B25]\]. Recombinant murine IFNγ was obtained from R&D Systems. Neutralizing anti-IFNγ and control antibodies were purchased from BD Biosciences. For all experiments a minimum of 3 sets of pooled BAL cells from 3-5 mice were used except where indicated.

Human subjects
--------------

The protocol was approved by the East Carolina University Institutional Review Board and written informed consent was obtained from all patients and control subjects. Healthy control subjects had no history of lung disease and were not on medication. PAP subjects were recruited from patients undergoing routine clinical evaluation. The diagnosis of idiopathic PAP was confirmed by histopathological examination of material from open lung or transbronchial biopsies as previously described \[[@B29]\]. Alveolar macrophages were derived from bronchoalveolar lavage (BAL) obtained by fiberoptic bronchoscopy as previously described \[[@B29]\]. Differential cell counts were obtained from cytospins stained with a modified Wright's stain. For PAP patients, the mean BAL cell percentages (means ± SEMs) were: alveolar macrophages, 83 ± 9%, and lymphocytes, 10 ± 5%. Healthy control values were: alveolar macrophages, 93 ± 2% and lymphocytes, 7 ± 2%. For *in vitro* culture, BAL cells were plated into 24-well plates (300,000 alveolar macrophages per well) or chamber slides (60,000 cells/well) as previously described \[[@B16]\].

RNA purification and analysis
-----------------------------

Total RNA was extracted from BAL cells or cultured alveolar macrophages and analyzed by Q-PCR as previously described \[[@B25]\]. RNA specimens were analyzed in duplicate using primer-probe sets for activin A, IL-10, iNOS, CCL2, CCL5, IL-6, IFNγ and GAPDH as previously described \[[@B25]\]. Data were normalized to GAPDH and expressed as fold change in mRNA expression compared to controls values as previously described \[[@B44]\].

Lentivirus plasmid and transduction
-----------------------------------

The self-inactivating lentivirus expression vector used here has been described previously \[[@B45]\]. Construction of the lentivirus-PPARγ (lenti-PPARγ) and control lentivirus construct has also been described in detail \[[@B20],[@B25]\]. Control consisted of a lentivirus vector expressing Enhanced Green Fluorescent Protein (eGFP) (lenti-EGFP). Animals received 50 ug of lentivirus vector in 50 μl PBS or PBS alone (sham) by intratracheal instillation. After 10 days, five animals per group were lavaged, BAL differential counts were obtained and RNA was extracted.

Activin A and follistatin protein assays
----------------------------------------

Activin A or follistatin proteins (pg/ml) in BAL fluids or conditioned media from cultured alveolar macrophages were quantified by ELISA according to the manufacturer's instructions (Serotec, Raleigh, NC; R&D Systems, Minneapolis, MN).

Immunocytochemistry
-------------------

Immunocytochemistry for IFNγ was carried out on cytospin samples from freshly isolated BAL cells using rat anti-mouse IFNγ (Santa Cruz Biotechnology,1:100) followed by goat anti-rat IgG (Invitrogen) as described \[[@B25]\]. Slides were counter-stained with DAPI (Invitrogen) to allow nuclear localization.

Statistics
----------

Data were analyzed by student's t-test using Prism software (GraphPad). Values from treated cells were compared to untreated. Significance was defined as p ≤ 0.05.

Abbreviations
=============

AM: Alveolar macrophage; GM-CSF: Granulocyte macrophage colony stimulating factor; PAP: Pulmonary alveolar proteinosis; BAL: Bronchoalveolar lavage; PPARγ: Peroxisome proliferator activated receptor; IFNγ: Interferonγ; iNOS: Inducible nitric oxide synthetase.
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